Andy Roddick defends Serena Williams' GLP-1 weight loss amid comeback talk

Former tennis star Andy Roddick has voiced support for Serena Williams' use of GLP-1 medication in her weight-loss efforts, suggesting it could aid a potential return to the court. Williams has shared how the treatment improved her health, while speculation grows following her inclusion in the anti-doping pool and practice sessions with younger players. Roddick emphasized the benefits for injury prevention during training.

In a recent episode of the Served podcast, Andy Roddick addressed criticism of Serena Williams' use of GLP-1 medication for weight loss. He stated that if he were attempting a comeback, he would prioritize rapid weight reduction to facilitate safer training. "I can tell you something that I think I know for a fact, right? I’m not Serena. I can’t play anymore. I stink. And if I decided that I wanted to come back, guess what I would be doing immediately? Immediately, I’d be dropping 20 pounds as fast as I can," Roddick said.

Roddick argued that starting lighter reduces injury risks during preparation, which is a major hurdle for returning athletes. "I would be taking those drugs because you know what becomes easier when you are 20 pounds lighter? Actually, getting back to the training that you need without getting injured to get back on tour," he explained. He added, "What it does is shortens the timeline for training and mitigates a lot of the risk in because the thing with getting back is like you get injured training, injured training, injured training, you can’t get back. Right."

Williams first discussed her use of the medication in an August 2025 interview with People Magazine and reinforced it in a Super Bowl XL advertisement in 2026. In a January 2026 interview with Today.com, she highlighted health improvements: "My blood sugar is better. I was able to lower my cholesterol by 30%. Some of these numbers [previous high cholesterol levels] are from when I was literally winning Grand Slams. It wasn’t, like, just playing tennis. I was dominating. I was at risk for heart disease, and I didn’t even know. … That’s scary."

Comeback rumors intensified after Williams' name appeared in the tennis anti-doping testing pool, a step often required for returning players. On the Today show in January 2026, she responded ambiguously: "I’m just having fun and enjoying my life right now," adding, "I don’t know, I’m just going to see what happens."

American player Alycia Parks recently practiced with Williams and commented on her fitness. "I actually practiced with her last Monday. And I messaged her yesterday. She’s definitely a good mentor to me, and she’s helped me a lot, especially in my practices," Parks told Tennis Majors. She added, "She is in great shape. So I think she would kill it on tour."

Support for Williams continues to build in the tennis community as discussions of a potential return, possibly emulating sister Venus, persist.

Artikel Terkait

Serena Williams, fit and transformed, poses athletically with tennis racket against Super Bowl ad for Zepbound weight loss drug.
Gambar dihasilkan oleh AI

Serena Williams appears in Super Bowl ad for weight loss medication

Dilaporkan oleh AI Gambar dihasilkan oleh AI

Serena Williams is set to feature in a Super Bowl commercial promoting the telehealth firm Ro and its GLP-1 weight loss medication Zepbound. The 44-year-old tennis legend discusses her body transformation, having lost up to 15.4kg since starting the treatment. The ad comes amid ongoing speculation about a potential return to professional tennis.

The International Tennis Integrity Agency has officially reinstated Serena Williams as an active player, removing her from the retired list on February 22, 2026. This move follows her rejoining the anti-doping testing pool last year, making her eligible for tournaments. Her former coach Rick Macci expressed certainty about a comeback, citing her intensive training.

Dilaporkan oleh AI

Bintang country Jelly Roll telah menurunkan hampir 300 pon dalam dua tahun tanpa menggunakan obat GLP-1 populer seperti Ozempic. Penyanyi berusia 41 tahun itu membuka diri di Men's Health tentang mengatasi kecanduan makanannya melalui terapi. Dari masalah testosteron rendah hingga romansa yang menyala kembali, dia membocorkan semua cerita transformasional.

Tiga ulasan Cochrane yang dipesan oleh Organisasi Kesehatan Dunia mengevaluasi agonis reseptor GLP-1 seperti tirzepatide, semaglutide, dan liraglutide untuk penurunan berat badan pada orang dengan obesitas. Obat-obatan ini menunjukkan pengurangan berat badan yang substansial dibandingkan plasebo, tetapi peneliti mencatat keterbatasan data jangka panjang dan pengaruh pendanaan industri. Efek samping seperti mual umum terjadi, memunculkan pertanyaan tentang akses yang lebih luas dan keamanan.

Dilaporkan oleh AI

Coco Gauff's quarterfinal exit at the 2026 Australian Open turned controversial when footage of her smashing her racket went viral. Tennis legend Serena Williams offered encouragement, while several players raised concerns about privacy in player areas. The incident highlighted the emotional pressures faced by athletes.

Top tennis players Carlos Alcaraz, Jannik Sinner and Aryna Sabalenka were instructed to remove their Whoop fitness trackers during the 2026 Australian Open. The devices, approved for ATP and WTA tours, remain banned at Grand Slams amid ongoing debates over player welfare and data rules. Tournament organizers are in discussions to potentially allow them in the future.

Dilaporkan oleh AI

Petenis pensiunan Eugenie Bouchard membahas keguncangan dalam hidupnya setelah tampil di final Wimbledon 2014, yang membawa ketenaran mendadak dan ekspektasi tinggi. Dia menggambarkan fase pemberontak yang mencakup perubahan gaya rambut drastis, menyebabkan hilangnya kesepakatan sponsor. Kini fokus pada pickleball, Bouchard menekankan kompleksitas di balik citra publiknya.

 

 

 

Situs web ini menggunakan cookie

Kami menggunakan cookie untuk analisis guna meningkatkan situs kami. Baca kebijakan privasi kami untuk informasi lebih lanjut.
Tolak